NCT06062810View on ClinicalTrials.gov

Pharmacogenomics ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

June 21, 2025

Primary Completion Date

December 18, 2026

Study Completion Date

December 28, 2026

Conditions
Breast Cancer
Interventions
DRUG

Raloxifene - Usual

"* Generic-1 - raloxifene hydrochloride tablet~* Raloxifene 60 mg taken orally daily"

DRUG

Raloxifene - Study

"* Generic-2 - Raloxifene tablet~* Raloxifene 60 mg taken orally daily"

Trial Locations (1)

20853

Medicine Invention Design, Inc. - IORG0007849 - NPI 1023387701, Rockville

All Listed Sponsors
lead

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

INDUSTRY